Key Highlights

  • ABOS shares trading down 85.77% to $0.33, implying a prior close near $2.32.
  • Phase 2 ALTITUDE-AD missed its primary iADRS endpoint at 18 months at both the 35 mg/kg and 50 mg/kg doses.
  • Key secondary endpoints, including CDR-SB, also failed to reach statistical significance.
  • ARIA-E edema occurred in about 10% of sabirnetug-treated participants in the 542-person study.
  • Cash and marketable securities stood at $110.2 million as of June 30, 2026.

Sabirnetug Misses Primary Endpoint in 542-Patient ALTITUDE-AD Study

Acumen Pharmaceuticals (NASDAQ:ABOS) shares are trading down 85.77% at $0.33 today after the company reported topline results from its Phase 2 ALTITUDE-AD trial of sabirnetug in early Alzheimer's disease. The study did not meet its primary endpoint, the change from baseline in the iADRS score at 18 months versus placebo, at either the 35 mg/kg or 50 mg/kg dose.

Acumen, based in Newton, Massachusetts, is a clinical-stage biopharmaceutical company developing antibodies that target toxic soluble amyloid Beta oligomers. Sabirnetug, also known as ACU193, was its lead candidate and was dosed by infusion every four weeks in the 542-participant study.

Key secondary endpoints, including the CDR-SB measure of dementia severity, also failed to reach statistical significance. The company reported no meaningful difference between either sabirnetug arm and placebo.

Amyloid Plaque Reduction and a 10% ARIA-E Rate Fail to Translate Into Clinical Benefit

Amyloid PET imaging showed statistically significant reductions in plaque burden from baseline at both doses at weeks 36 and 76, according to the company. That biological effect did not produce a measurable difference in cognition or function against placebo.

Sabirnetug was described as generally well tolerated, though amyloid-related imaging abnormalities with edema, known as ARIA-E, occurred in about 10% of treated participants. Acumen said additional fluid biomarker and imaging data are due in the coming weeks but are not expected to change the efficacy conclusions.

The topline package covers the full 18-month treatment period. The company's release described the plaque reduction without giving numerical values.

Development Halted, Cash Conservation and Strategic Options on the Table

Acumen said it will stop developing sabirnetug, including the open-label extension, and will evaluate strategic options. These include its Enhanced Brain Delivery program, which was developed with JCR Pharmaceuticals and is aimed at improving antibody transport across the blood-brain barrier. The company also plans cash conservation measures, though it gave no figures for workforce or cost changes.

At the end of June, Acumen held $110.2 million in cash and marketable securities, down from $128.4 million at the end of March, and said that supported operations into early 2027. It posted a second-quarter net loss of $32.7 million, or $0.45 per share, on about 72.3 million shares outstanding. At $0.33, the Market Value of those shares works out to roughly $24 million, well below the June cash balance.

Second-quarter Research and Development expense fell to $27.8 million from $37.1 million a year earlier, mainly on lower manufacturing, materials and trial-site costs tied to ALTITUDE-AD. The share count has also grown, from about 60.6 million at the end of 2025 to roughly 72.3 million in June.

What Follows the ALTITUDE-AD Failure: Pending Biomarker Data and a Strategic Review

With its only clinical-stage candidate discontinued, Acumen's near-term path rests on the outcome of its strategic review and the Enhanced Brain Delivery program. Investors will watch for the promised biomarker and imaging data in the coming weeks, any detail on cash conservation, and whether the company discloses a revised cash runway.